Headlines Covid-19 Specialties Trending Feeds Videos

Mashup Score: 1

JAMA Network

This systematic review and meta-analysis examines the relative risk of hepatotoxicity of new-generation BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (TKIs) vs imatinib among patients

  • Although BCR-ABL TKIs can significantly improve the survival rate of chronic myeloid leukemia, it is accompanied by severe hepatotoxicity. Bosutinib, nilotinib and ponatinib were associated with an increased risk of hepatotoxicity compared with imatinib. https://t.co/qPCtmRXPli - view on twitter